Found: 83
Select item for more details and to access through your institution.
Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 6, p. 729, doi. 10.1002/ajh.25077
- By:
- Publication type:
- Article
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 2, p. 179, doi. 10.1002/ajh.24223
- By:
- Publication type:
- Article
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
- Published in:
- 1994
- By:
- Publication type:
- journal article
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
- Published in:
- Cold Spring Harbor Molecular Case Studies, 2021, v. 7, n. 1, p. 1, doi. 10.1101/mcs.a005934
- By:
- Publication type:
- Article
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T‐cell lymphoma.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 1, p. 35, doi. 10.1111/ejh.13239
- By:
- Publication type:
- Article
Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma.
- Published in:
- American Journal of Hematology, 1992, v. 39, n. 3, p. 163, doi. 10.1002/ajh.2830390303
- By:
- Publication type:
- Article
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 483, doi. 10.1016/j.clml.2021.12.016
- By:
- Publication type:
- Article
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 1, p. 24, doi. 10.1016/j.clml.2021.07.017
- By:
- Publication type:
- Article
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S248, doi. 10.1016/j.clml.2019.07.153
- By:
- Publication type:
- Article
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
- Published in:
- Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01579-w
- By:
- Publication type:
- Article
Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study.
- Published in:
- European Journal of Endocrinology, 2020, v. 183, n. 4, p. 453, doi. 10.1530/EJE-19-0506
- By:
- Publication type:
- Article
Immunothérapies innovantes dans le lymphome de Hodgkin réfractaire/en rechute (rrLH).
- Published in:
- Revue Immunite & Cancer, 2021, v. 5, n. 3, p. 147
- By:
- Publication type:
- Article
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 8, p. 1, doi. 10.1038/s41408-021-00539-8
- By:
- Publication type:
- Article
Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 1, p. 210, doi. 10.1046/j.1365-2141.2002.03565.x
- By:
- Publication type:
- Article
Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.
- Published in:
- British Journal of Haematology, 2001, v. 113, n. 3, p. 737, doi. 10.1046/j.1365-2141.2001.02801.x
- By:
- Publication type:
- Article
The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): a novel translocation involving the FGFR1 gene.
- Published in:
- British Journal of Haematology, 2000, v. 111, n. 2, p. 647, doi. 10.1046/j.1365-2141.2000.02355.x
- By:
- Publication type:
- Article
Prognostic Value of <sup>18</sup>F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 1, p. 156, doi. 10.2967/jnumed.123.265872
- By:
- Publication type:
- Article
Validation of the ΔSUV<sub>max</sub> for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 11, p. 1706, doi. 10.2967/jnumed.123.265871
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1925, doi. 10.2967/jnumed.121.263501
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263501
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263501
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263501
- By:
- Publication type:
- Article
Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.242412
- By:
- Publication type:
- Article
Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.242412
- By:
- Publication type:
- Article
Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.242412
- By:
- Publication type:
- Article
Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.242412
- By:
- Publication type:
- Article
Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.242412
- By:
- Publication type:
- Article
Early <sup>18</sup>F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.232827
- By:
- Publication type:
- Article
18F-FDG-PET dissemination features in diffuse large B cell lymphoma are predictive of outcome.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.229450
- By:
- Publication type:
- Article
Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 4, p. 714, doi. 10.2967/jnumed.117.205351
- By:
- Publication type:
- Article
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 4, p. 589, doi. 10.2967/jnumed.117.193946
- By:
- Publication type:
- Article
Interim PET in Hodgkin Lymphoma: Is It So Useless?
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 7, p. 1180, doi. 10.2967/jnumed.117.190462
- By:
- Publication type:
- Article
Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 2, p. 276, doi. 10.2967/jnumed.116.180406
- By:
- Publication type:
- Article
Interim <sup>18</sup>F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 4, p. 569, doi. 10.2967/jnumed.113.130609
- By:
- Publication type:
- Article
In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with <sup>18</sup>F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy.
- Published in:
- Journal of Nuclear Medicine, 2013, v. 54, n. 8, p. 1244, doi. 10.2967/jnumed.112.114710
- By:
- Publication type:
- Article
c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma.
- Published in:
- Journal of Pathology: Clinical Research, 2021, v. 7, n. 6, p. 604, doi. 10.1002/cjp2.223
- By:
- Publication type:
- Article
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 18, p. 6565, doi. 10.1002/cam4.3298
- By:
- Publication type:
- Article
Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 2, p. 417, doi. 10.3390/diagnostics12020417
- By:
- Publication type:
- Article
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 423, doi. 10.1007/s40262-021-01081-3
- By:
- Publication type:
- Article
Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials.
- Published in:
- Acta Oncologica, 2023, v. 62, n. 7, p. 744, doi. 10.1080/0284186X.2023.2195561
- By:
- Publication type:
- Article
Trends in excess mortality in follicular lymphoma at a population level.
- Published in:
- European Journal of Haematology, 2015, v. 94, n. 2, p. 120, doi. 10.1111/ejh.12403
- By:
- Publication type:
- Article
Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?
- Published in:
- Current Hematologic Malignancy Reports, 2012, v. 7, n. 3, p. 193, doi. 10.1007/s11899-012-0129-y
- By:
- Publication type:
- Article
Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 3, p. 519, doi. 10.1002/cncr.33938
- By:
- Publication type:
- Article
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 2, p. 256, doi. 10.1111/bjh.18642
- By:
- Publication type:
- Article
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA).
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 203, doi. 10.1111/bjh.18198
- By:
- Publication type:
- Article
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres<sup>†</sup>
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. e94, doi. 10.1111/bjh.17279
- By:
- Publication type:
- Article
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 1, p. 84, doi. 10.1111/bjh.16300
- By:
- Publication type:
- Article
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <italic>MYC</italic>/<italic>PVT1</italic> predicts patient outcome in two independent cohorts.
- Published in:
- 2018
- By:
- Publication type:
- Abstract